ACTRN12618000977279尚未招募1 期
A Phase 1 Study on the safety and maximum tolerated dose of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein, in Patients with Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
招募中
1 期
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
已完成
不适用
A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients with Advanced or Treatment Refractory Haematological Diseases or Lymphoid MalignanciesBlood cancerlymph cancer1001884910025323NL-OMON33977Chroma Therapeutics Ltd.15
招募中
1 期
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid TumorsJPRN-jRCT2031220663Eiji Ueda203
已完成
1 期
A Phase 1 Study Exploring the Safety, Tolerability, and Pharmacokinetics ofINCB086550 in Japanese Participants With Advanced Solid TumorsSolid TumorsJPRN-jRCT2031200277eda Eiji3